Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial

Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized clinical trial to identify markers associated with amyloid beta pathology, disease progression, and response to Li treatment. In the LATTICE trial, 80 older adults with mild cognitive impairment (MCI) were randomly assigned to receive either low-dose Li carbonate or placebo for two years. Longitudinal plasma samples were analyzed using the NULISAseq CNS Disease Panel 120 proteomic panel. Baseline protein levels were compared according to randomized treatment assignment, amyloid beta PET status, and MCI subtype. Analyses included longitudinal changes in protein levels associated with treatment and time, associations between baseline protein levels and subsequent cognitive, functional, and neuroimaging trajectories, and the influence of baseline protein levels on Li treatment effects. Among the 80 participants, 62 had amnestic MCI and 21 were positive on amyloid beta PET. Baseline proteomic differences were more strongly associated with amyloid beta PET status than with randomized treatment assignment. Plasma p-tau217 concentrations were elevated in individuals who were positive on amyloid beta PET and remained significant after false discovery rate correction. Over time, CALB2 and TREM2 exhibited nominal treatment-by-time interactions in the full cohort, while in the amnestic MCI subgroup, CALB2, TREM2, and amyloid beta 40 demonstrated nominal effects. None persisted after multiple-testing correction. GDF15 showed the most consistent associations with CDR Sum of Boxes trajectories and treatment-effect modification that remained significant after false discovery rate correction in the amnestic MCI subgroup, whereas p-tau217 was most consistently associated with hippocampal volume trajectories. Other protein-outcome associations were exploratory. Plasma proteomics identified distinct molecular patterns associated with amyloid beta pathology and the MCI phenotype, along with exploratory evidence of Li-associated protein changes. Plasma GDF15 and p-tau217 emerged as potential markers of clinical progression and treatment-response heterogeneity, warranting validation in larger, adequately powered trials.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.14.26368038
Primary Topic
Dementia and Cognitive Impairment Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial

Marissa F. Farinas, Laisze Lee, Sarah K. Royse, Anuradha Sehrawat et al.
1 links
medRxiv
Dementia and Cognitive Impairment Research
preprint

Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial

Marissa F. Farinas, Laisze Lee, Sarah K. Royse, Anuradha Sehrawat, Andrea M. Weinstein, Thomas K. Karikari, Ariel G. Gildengers, Brian J. Lopresti, James E. Emanuel, Meryl A. Butters, Ruyu Shi, Xuemei Zeng
preprint en

Abstract

Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized clinical trial to identify markers associated with amyloid beta pathology, disease progression, and response to Li treatment. In the LATTICE trial, 80 older adults with mild cognitive impairment (MCI) were randomly assigned to receive either low-dose Li carbonate or placebo for two years. Longitudinal plasma samples were analyzed using the NULISAseq CNS Disease Panel 120 proteomic panel. Baseline protein levels were compared according to randomized treatment assignment, amyloid beta PET status, and MCI subtype. Analyses included longitudinal changes in protein levels associated with treatment and time, associations between baseline protein levels and subsequent cognitive, functional, and neuroimaging trajectories, and the influence of baseline protein levels on Li treatment effects. Among the 80 participants, 62 had amnestic MCI and 21 were positive on amyloid beta PET. Baseline proteomic differences were more strongly associated with amyloid beta PET status than with randomized treatment assignment. Plasma p-tau217 concentrations were elevated in individuals who were positive on amyloid beta PET and remained significant after false discovery rate correction. Over time, CALB2 and TREM2 exhibited nominal treatment-by-time interactions in the full cohort, while in the amnestic MCI subgroup, CALB2, TREM2, and amyloid beta 40 demonstrated nominal effects. None persisted after multiple-testing correction. GDF15 showed the most consistent associations with CDR Sum of Boxes trajectories and treatment-effect modification that remained significant after false discovery rate correction in the amnestic MCI subgroup, whereas p-tau217 was most consistently associated with hippocampal volume trajectories. Other protein-outcome associations were exploratory. Plasma proteomics identified distinct molecular patterns associated with amyloid beta pathology and the MCI phenotype, along with exploratory evidence of Li-associated protein changes. Plasma GDF15 and p-tau217 emerged as potential markers of clinical progression and treatment-response heterogeneity, warranting validation in larger, adequately powered trials.

medRxiv
University of Pittsburgh (US)
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon